XIAOMI-W
01810
MEITUAN-W
03690
NTES-S
09999
TRIP.COM-S
09961
TENCENT
00700
Gacos Pharmaceutical Group Co., Ltd. is committed to providing breakthrough treatment solutions for patients. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platform has technology to develop allosteric inhibitors of protein phosphatase, KRAS, and other transcription factors. Gacos has received investment from several biotechnology-specialized investment institutions, including Qiming Venture Capital, Eli Lilly Asia Fund, Gao Lin, and Taiwan Yu Sheng.